IL301622A - Methods for treating degenerative joint disease with cannabidiol gel through the skin - Google Patents
Methods for treating degenerative joint disease with cannabidiol gel through the skinInfo
- Publication number
- IL301622A IL301622A IL301622A IL30162223A IL301622A IL 301622 A IL301622 A IL 301622A IL 301622 A IL301622 A IL 301622A IL 30162223 A IL30162223 A IL 30162223A IL 301622 A IL301622 A IL 301622A
- Authority
- IL
- Israel
- Prior art keywords
- cbd
- cannabidiol
- osteoarthritis
- patients
- pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545468P | 2017-08-14 | 2017-08-14 | |
| US201862661733P | 2018-04-24 | 2018-04-24 | |
| PCT/IB2018/056090 WO2019034985A1 (en) | 2017-08-14 | 2018-08-13 | METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL301622A true IL301622A (en) | 2023-05-01 |
Family
ID=65362584
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301622A IL301622A (en) | 2017-08-14 | 2018-08-13 | Methods for treating degenerative joint disease with cannabidiol gel through the skin |
| IL272593A IL272593A (en) | 2017-08-14 | 2020-02-11 | Methods of treatment of osteoarthritis with transdermal cannabidiol gel |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272593A IL272593A (en) | 2017-08-14 | 2020-02-11 | Methods of treatment of osteoarthritis with transdermal cannabidiol gel |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20200170963A1 (https=) |
| EP (1) | EP3668500A4 (https=) |
| JP (3) | JP2020530857A (https=) |
| KR (1) | KR20200054171A (https=) |
| AU (2) | AU2018318425A1 (https=) |
| BR (1) | BR112020003025A2 (https=) |
| CA (1) | CA3072849A1 (https=) |
| IL (2) | IL301622A (https=) |
| JO (1) | JOP20200031A1 (https=) |
| MX (1) | MX2020001768A (https=) |
| WO (1) | WO2019034985A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL301622A (en) * | 2017-08-14 | 2023-05-01 | Zynerba Pharmaceuticals Inc | Methods for treating degenerative joint disease with cannabidiol gel through the skin |
| US12582664B2 (en) | 2017-09-28 | 2026-03-24 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| ES2907325T3 (es) | 2017-09-28 | 2022-04-22 | Zynerba Pharmaceuticals Inc | Tratamiento de síndrome del cromosoma X frágil y autismo con cannabidiol |
| MX2021007076A (es) | 2018-12-14 | 2021-08-11 | Zynerba Pharmaceuticals Inc | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. |
| CN114650809A (zh) | 2019-10-03 | 2022-06-21 | 斯塔顿治疗公司 | 屈大麻酚的透皮递送 |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| CA3155176A1 (en) | 2019-10-11 | 2021-04-15 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| CA3156239A1 (en) * | 2019-10-13 | 2021-04-22 | Figene, Llc | Cannabidiol adjuvant therapy for treatment of disc degenerative disease |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| CA3155181A1 (en) | 2019-10-14 | 2021-04-22 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal delivery of cannabidiol |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| JP7830358B2 (ja) * | 2020-06-29 | 2026-03-16 | ハーモニー・バイオサイエンシズ・マネージメント・インコーポレイテッド | カンナビジオールによる脆弱ｘ症候群の処置 |
| JP2024513961A (ja) * | 2021-04-12 | 2024-03-27 | パイク セラピューティクス インコーポレイテッド | カンナビジオールの経皮送達 |
| EP4098254A1 (en) * | 2021-06-04 | 2022-12-07 | Assistance Publique, Hopitaux De Paris | Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease |
| WO2024085581A1 (ko) * | 2022-10-17 | 2024-04-25 | (주)인벤티지랩 | 염증성 질환의 치료 또는 예방을 위한 서방형 주사용 조성물 및 이의 제조 방법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9807639D0 (en) * | 1998-04-14 | 1998-06-10 | Kennedy Rheumatology Inst | Anti-inflammatory agents |
| US8449908B2 (en) * | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| GB2414933B (en) * | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
| JP5240925B2 (ja) * | 2005-05-25 | 2013-07-17 | カロシン ファーマ， インコーポレイテッド | 変形性関節症を処置するための方法および組成物 |
| US20090247619A1 (en) * | 2008-03-06 | 2009-10-01 | University Of Kentucky | Cannabinoid-Containing Compositions and Methods for Their Use |
| EP3056217B1 (en) * | 2008-12-22 | 2021-06-30 | The University of Melbourne | Osteoarthritis treatment |
| MX2011011514A (es) * | 2009-04-28 | 2011-11-18 | Alltranz Inc | Formulaciones de canabidiol y metodos para utilizarlas. |
| MX2011011445A (es) * | 2009-04-29 | 2011-11-18 | Univ Kentucky Res Found | Composiciones que contienen cannabinoides y metodos para su uso. |
| PT2473475T (pt) * | 2009-08-31 | 2017-08-02 | Zynerba Pharmaceuticals Inc | Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas |
| CN113583951A (zh) * | 2012-06-26 | 2021-11-02 | 细胞创新知识产权有限公司 | 通过超声空化从脂肪组织分离干细胞及使用方法 |
| US20160015818A1 (en) * | 2014-07-18 | 2016-01-21 | Medipath, Inc. | Compositions and methods for physiological delivery using cannabidiol |
| IL301622A (en) * | 2017-08-14 | 2023-05-01 | Zynerba Pharmaceuticals Inc | Methods for treating degenerative joint disease with cannabidiol gel through the skin |
-
2018
- 2018-08-13 IL IL301622A patent/IL301622A/en unknown
- 2018-08-13 KR KR1020207005446A patent/KR20200054171A/ko not_active Ceased
- 2018-08-13 AU AU2018318425A patent/AU2018318425A1/en not_active Abandoned
- 2018-08-13 JO JOP/2020/0031A patent/JOP20200031A1/ar unknown
- 2018-08-13 CA CA3072849A patent/CA3072849A1/en active Pending
- 2018-08-13 WO PCT/IB2018/056090 patent/WO2019034985A1/en not_active Ceased
- 2018-08-13 JP JP2020509441A patent/JP2020530857A/ja active Pending
- 2018-08-13 MX MX2020001768A patent/MX2020001768A/es unknown
- 2018-08-13 BR BR112020003025-2A patent/BR112020003025A2/pt unknown
- 2018-08-13 EP EP18846438.2A patent/EP3668500A4/en active Pending
-
2020
- 2020-02-11 IL IL272593A patent/IL272593A/en unknown
- 2020-02-12 US US16/788,882 patent/US20200170963A1/en not_active Abandoned
-
2023
- 2023-05-29 JP JP2023087510A patent/JP7590803B2/ja active Active
- 2023-06-13 US US18/209,267 patent/US20240189255A1/en not_active Abandoned
- 2023-10-06 US US18/482,799 patent/US20240148669A1/en not_active Abandoned
-
2024
- 2024-08-15 AU AU2024205778A patent/AU2024205778A1/en active Pending
- 2024-11-12 JP JP2024197147A patent/JP2025024068A/ja active Pending
-
2025
- 2025-01-01 US US19/007,534 patent/US20250268843A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023109969A (ja) | 2023-08-08 |
| WO2019034985A1 (en) | 2019-02-21 |
| EP3668500A4 (en) | 2021-04-28 |
| US20240189255A1 (en) | 2024-06-13 |
| EP3668500A1 (en) | 2020-06-24 |
| AU2018318425A1 (en) | 2020-02-27 |
| AU2024205778A1 (en) | 2024-09-05 |
| US20240148669A1 (en) | 2024-05-09 |
| JOP20200031A1 (ar) | 2020-02-12 |
| KR20200054171A (ko) | 2020-05-19 |
| JP2020530857A (ja) | 2020-10-29 |
| MX2020001768A (es) | 2020-12-03 |
| US20200170963A1 (en) | 2020-06-04 |
| BR112020003025A2 (pt) | 2020-08-04 |
| JP7590803B2 (ja) | 2024-11-27 |
| IL272593A (en) | 2020-03-31 |
| CA3072849A1 (en) | 2019-02-21 |
| US20250268843A1 (en) | 2025-08-28 |
| JP2025024068A (ja) | 2025-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240189255A1 (en) | Methods of treatment of osteoarthritis with transdermal cannabidiol gel | |
| JP7650929B2 (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| JP7210564B2 (ja) | カンナビジオールによる脆弱ｘ症候群の処置 | |
| AU2021301406A1 (en) | Treatment of fragile x syndrome with cannabidiol | |
| EP4157236A1 (en) | Treatment of autism spectrum disorder with cannabidiol | |
| US20240342198A1 (en) | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance | |
| Gan et al. | Safety evaluation of fospropofol for sedation during minor surgical procedures | |
| TR201906742T4 (tr) | Tıbbi bir ürün ve tedavi. | |
| US20190021995A1 (en) | Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses | |
| HK1236391A1 (en) | Stabilized oxymetazoline formulations and their uses | |
| HK1236391B (en) | Stabilized oxymetazoline formulations and their uses |